Maple Syrup Urine Disease (MSUD)

1. Introduction / Definition

• Incidence: approximately 1 in 185,000 - 1 in 200,000 live births
• Inheritance: Autosomal recessive

2. Normal Metabolism of Branched-Chain Amino Acids

• All three BCAAs transfer their amino groups to α-ketoglutarate
• Catalyzed by branched-chain amino acid aminotransferase (requires vitamin B6 / pyridoxal phosphate)
• Products: corresponding α-keto acids (α-ketoisocaproate from leucine, α-keto-β-methylvalerate from isoleucine, α-ketoisovalerate from valine)

• The α-keto acids are decarboxylated by the BCKD complex
• BCKD uses coenzymes: thiamine pyrophosphate (TPP), lipoic acid, FAD, NAD⁺, and CoA
• Produces acyl-CoA derivatives + NADH + CO₂

3. Enzyme Defect in MSUD

• E1α (encoded by BCKDHA gene)
• E1β (encoded by BCKDHB gene)
• E2 (dihydrolipoyl transacylase, encoded by DBT gene)
• E3 (dihydrolipoyl dehydrogenase, encoded by DLD gene)

The E3 subunit is shared with two other important complexes: pyruvate dehydrogenase and α-ketoglutarate dehydrogenase. This is why E3 deficiency (type III MSUD) can additionally cause lactic acidosis and neurological complications.

4. Genetic Subtypes of MSUD

5. Pathophysiology

• Leucine is the primary neurotoxic agent - it causes cerebral edema by disrupting the blood-brain barrier and interfering with transport of other amino acids into the brain
• Accumulation leads to ketoacidosis (due to buildup of α-keto acids)
• Alloisoleucine (a stereoisomer of isoleucine) is pathognomonic - it forms via racemization of the keto acid and is not normally present in plasma
• The maple syrup odor is due to the accumulated α-keto acids, principally those derived from isoleucine

6. Clinical Features

Classic (Neonatal) Presentation:

• Normal birth and uneventful first 1-2 days of life
• By Day 3-5: poor feeding, vomiting, irritability
• Characteristic maple syrup odor of urine (also noticeable in ear wax)
• Ketonuria (ketones in urine)
• Neurological deterioration: lethargy → stupor → coma
• Hypotonia or hypertonia, decerebrate rigidity
• Seizures
• Irregular respirations
• Hypoglycemia
• If untreated: death within the first weeks of life
• If treatment is delayed: intellectual disability and irreversible brain damage

7. Diagnosis

Urine Tests:

• 2,4-Dinitrophenylhydrazine (DNPH) test - screening test; forms an insoluble yellow or chalky white precipitate with α-keto acids; positive in MSUD
• Urine organic acid analysis - shows characteristic branched-chain keto acids (α-ketoisocaproate, α-keto-β-methylvalerate, α-ketoisovalerate) and 2-hydroxyisovaleric acid during decompensation

Blood Tests:

• Plasma amino acid analysis - shows markedly elevated leucine, isoleucine, valine
• Presence of L-alloisoleucine in plasma is pathognomonic
• Elevated leucine is usually the most prominent

Newborn Screening:

• Tandem mass spectrometry (MS/MS) on a few drops of neonatal blood
• Detects elevated leucine and isoleucine with normal phenylalanine levels
• Prenatal diagnosis via enzyme activity in cultured amniotic cells or chorionic villus sampling is available

8. Treatment

Dietary Management (cornerstone):

• Synthetic formula free of BCAAs, supplemented with limited, carefully measured amounts of leucine, isoleucine, and valine sufficient for normal growth - but not enough to produce toxicity
• Leucine level is the primary marker monitored - it causes the neurological damage
• BCAAs cannot be completely eliminated because they are essential for protein synthesis and growth

Thiamine (Vitamin B1):

• Patients with thiamine-responsive MSUD are given large pharmacologic doses of thiamine which partially restores enzyme activity

Acute Decompensation:

• High-calorie, BCAA-free parenteral nutrition to stop catabolism
• Dialysis (hemodialysis or peritoneal dialysis) in severe cases to rapidly reduce BCAA levels

Liver Transplantation:

• Provides ~10% of normal BCKD activity (enough to prevent accumulation)
• Allows more liberal diet, but does not correct the enzyme defect in the brain

Key principle: Early diagnosis and lifelong dietary treatment are essential for normal development. During illness or stress (catabolic states), BCAA levels can rise rapidly because endogenous proteins (especially muscle) are broken down, releasing large amounts of BCAAs - this requires urgent management.

9. Summary Table (Quick Revision)

MAPLE SYRUP URINE DISEASE (MSUD)

DEFINITION

The urine smells like maple syrup or caramelized sugar, which gives the disease its name.

• Inheritance: Autosomal Recessive
• Incidence: ~1 in 1,85,000 live births
• Also called: Branched-Chain Ketonuria

NORMAL METABOLISM OF BCAAs (Background)

• BCAAs transfer their amino group to α-ketoglutarate
• Enzyme: Branched-chain amino acid aminotransferase (requires Vitamin B6)
• Products: corresponding α-keto acids

• α-keto acids are decarboxylated by the BCKD complex
• Coenzymes required: TPP, Lipoic acid, FAD, NAD⁺, CoA
• Products: Acyl-CoA derivatives + NADH + CO₂

ENZYME DEFECT

Important: The E3 subunit is shared with Pyruvate Dehydrogenase and α-Ketoglutarate Dehydrogenase complexes. So E3 deficiency also causes lactic acidosis.

TYPES / CLASSIFICATION

BIOCHEMICAL CHANGES

1. Leucine, Isoleucine, Valine accumulate in blood and urine
2. Their α-keto acids accumulate (responsible for toxic effects and maple syrup odor)
3. L-Alloisoleucine appears in plasma - a stereoisomer of isoleucine formed by racemization - this is pathognomonic (unique to MSUD)
4. Ketoacidosis develops due to accumulation of α-keto acids
5. Leucine is the primary neurotoxic agent - causes cerebral edema

CLINICAL FEATURES

1. Poor feeding and vomiting (first sign)
2. Maple syrup odor of urine (also detectable in ear wax)
3. Ketonuria (ketones in urine)
4. Neurological deterioration:
   • Lethargy → Stupor → Coma
   • Decerebrate rigidity
   • Seizures
5. Irregular respirations
6. Hypoglycemia
7. Changes in muscle tone (hypo or hypertonia)

If untreated: Fatal within first weeks of life If treatment delayed: Irreversible intellectual disability and brain damage

DIAGNOSIS

A. Urine Screening Tests:

• DNPH Test (2,4-Dinitrophenylhydrazine test):
  • Screening test for α-keto acids
  • Forms an insoluble yellow/white precipitate with keto acids
  • Positive in MSUD
• Urine Organic Acid Analysis: Detects branched-chain keto acids

B. Blood Tests:

• Plasma Amino Acid Analysis:
  • Markedly elevated Leucine, Isoleucine, Valine
  • Presence of L-Alloisoleucine (pathognomonic)
  • Leucine is usually the highest

C. Newborn Screening:

• Tandem Mass Spectrometry (MS/MS): Few drops of neonatal blood; detects elevated Leucine and Isoleucine
• Prenatal diagnosis by enzyme assay in amniotic fluid cells is available

TREATMENT

1. Dietary Restriction (Mainstay of treatment):

• Feed a synthetic formula free of BCAAs
• Supplemented with small, carefully monitored amounts of Leucine, Isoleucine, and Valine (needed for normal growth)
• Leucine levels are monitored closely as it causes neurological damage

2. Thiamine (Vitamin B1):

• Large pharmacological doses given to patients with thiamine-responsive MSUD
• Partially restores BCKD enzyme activity

3. Acute Decompensation Management:

• BCAA-free parenteral nutrition
• Hemodialysis or peritoneal dialysis to rapidly lower BCAA levels

4. Liver Transplantation:

• Provides ~10% of normal BCKD activity
• Allows more liberal diet; prevents acute episodes

Key Point: Early diagnosis + lifelong dietary treatment = normal development. During illness/fever, protein catabolism increases BCAA levels rapidly and needs urgent management.

MEMORY AID (Easy Trick)

• Missing enzyme = BCKD
• Substrates that accumulate = Leucine, Isoleucine, Valine
• Urine smells like maple syrup
• Damage = Brain (due to Leucine toxicity)

Leucine accumulates → Lethargy and coma → Lifelong diet needed

QUICK REVISION BOX